Vir Biotechnology, Inc. Form 4 (May 23, 2022) — SHARP PHILLIP A
Summary
A Form 4 for Phillip A. Sharp, a director of Vir Biotechnology, Inc. (VIR), reporting a 05/23/2022 acquisition of 6,405 shares of common stock, after which direct ownership stood at 115,147 shares. The same date shows a stock option (right to buy) on 12,810 shares at $24.14, expiring 05/22/2032. The form also lists indirect holdings of 44,444 shares in each of the irrevocable trusts named in the footnotes. Howard Horn signed as Attorney-in-Fact on 05/25/2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Vir Biotechnology, Inc. Form 4 (May 23, 2022) — SHARP PHILLIP A.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-vir-4-filed2022-05-25-0001209191-22-031961-e7a2ceec95/
, SHA-256 d34c6c25af6fa04ee7547025bc9299918f40f307d6660e8b52b98aeaf123d9b8.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * SHARP PHILLIP A (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | SHARP PHILLIP A | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 05/23/2022 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock | 05/23/2022 | A | 6,405 | A | $ 0.00 | 115,147 | D Common Stock | 44,444 | I | See footnote (1) Common Stock | 44,444 | I | See footnote (2) Common Stock | 44,444 | I | See footnote (3) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Stock Option (Right to Buy) | $ 24.14 | 05/23/2022 | A | 12,810 | 05/23/2023 | 05/22/2032 | Common Stock | 12,810 | $ 0.00 | 12,810 | D Explanation of Responses: 1. The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee. 2. The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee. 3. The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee. Remarks: /s/ Howard Horn, Attorney-in-Fact | 05/25/2022 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_VIR_4_filed2022-05-25_0001209191-22-031961.xml
- Size
- 17,902 bytes
- SHA-256
- d34c6c25af6fa04ee7547025bc9299918f40f307d6660e8b52b98aeaf123d9b8
- Original
- www.sec.gov